GS 2888

Drug Profile

GS 2888

Latest Information Update: 22 Nov 1999

Price : $50

At a glance

  • Originator Gilead Sciences; GlaxoSmithKline
  • Class Antineoplastics
  • Mechanism of Action Cell membrane permeability enhancers
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Discontinued Cancer

Most Recent Events

  • 22 Nov 1999 Investigation in Cancer in USA (Unknown route)
  • 21 Sep 1998 No-Development-Reported for Cancer in USA (Unknown route)
  • 21 Nov 1996 Preclinical development for Cancer in USA (Unknown route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top